calcium-fructoborate and Osteoarthritis

Our objective was to evaluate the short-term effects of calcium fructoborate (CFB) on gait, joint range of motion, serum inflammatory markers, and owner perception of pain in client-owned dogs. We used 59 osteoarthritic dogs with impairment, with dogs being randomly assigned to 4 treatments: placebo (60 mg fructose; = 15), low dose (69 mg CFB; = 14), high dose (127 mg CFB; = 14), or combination (69 mg CFB, 500 mg glucosamine hydrochloride and 200 mg chondroitin sulfate; = 16). Dogs up to 22.9 kg received 1 capsule/d, while dogs weighing 23 to 50 kg received 2 capsules/d. A physical examination, radiographs, goniometry measurements, gait analysis, blood sample collection, and a canine brief pain inventory questionnaire were performed on d 0 and 28. Change from baseline values were statistically analyzed among groups. After 28 d, dogs fed the low and high doses had an improved ( < 0.05) ability to rise from a lying position compared to placebo. Dogs fed the high dose also had a greater ( = 0.05) increase in soluble receptor for advanced glycation end products concentration than dogs fed the placebo. Sub-analysis of only large dogs (> 23 kg) showed that dogs fed the low dose had decreased ( < 0.05) pain severity score and pain at its worst compared to dogs fed the placebo. Large dogs fed the low dose also were shown to improve ( < 0.05) in their ability to rise from a lying position compared to dogs fed the placebo. Overall, CFB supplementation was well-tolerated and may aid in mitigating joint discomfort in dogs.

Topics: Animals; Borates; Calcium, Dietary; Dietary Supplements; Dog Diseases; Dogs; Double-Blind Method; Fructose; Gait; Inflammation; Joints; Osteoarthritis; Pain; Pain Measurement; Random Allocation; Range of Motion, Articular

The objective of this pilot study was to determine whether 15 days of dietary supplementation with calcium fructoborate could acutely modulate inflammatory and lipid blood markers in individuals diagnosed with primary osteoarthritis. During 2 weeks, a placebo-controlled, randomized, double-blind study was conducted on 116 subjects that were initially recruited. Seventy-two subjects started the study, being divided into four groups, and only 60 completed the study as designed. The aim was to compare the effects of calcium fructoborate to placebo on subjects diagnosed with knee primary osteoarthritis. The obtained outcomes were inflammation biomarkers (C-reactive protein, fibrinogen, and erythrocyte sedimentation rate) and lipid markers (triglycerides, total cholesterol, LDL cholesterol, and HDL cholesterol). No serious adverse events were reported. The calcium fructoborate showed beneficial effect on the inflammatory markers for all groups subjected to the treatment when compared with the placebo group and slight changes in the lipid metabolism. This study suggests that short-term (2 weeks) calcium fructoborate supplementation in patients with osteoarthritis symptoms has a favorable prognosis on inflammation diseases.

Topics: Aged; Aged, 80 and over; Blood Sedimentation; Borates; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Dietary Supplements; Double-Blind Method; Dyslipidemias; Female; Fibrinogen; Fructose; Humans; Inflammation; Lipid Metabolism; Male; Middle Aged; Osteoarthritis; Pilot Projects; Treatment Outcome; Triglycerides

To examine efficacy and tolerance of the drug Bora-Bora in patients with osteoarthrosis.. Bora-Bora and nimesulid were given to 20 patients with a verified diagnosis of osteoarthrosis (OA). 20 control patients received nimesulid alone. Treatment efficacy was evaluated by quantitative parameters of articular syndrome, indices of periarticular muscles affection estimated before the treatment, 2, 6 and 8 weeks after the start of the treatment. Ultrasonic investigation of the joints and periarticular tissues was conducted before and after the treatment course.. The response to Bora-Bora was seen on day 10 of therapy. Bora-Bora attenuated pain syndrome in the joints and periarticular tissues, improved joint function more effectively than nimesulid (p < 0.05). Bora-Bora is a good anelgetic. It is well tolerated and can be recommended for OA treatment.

Topics: Anti-Inflammatory Agents, Non-Steroidal; Borates; Dietary Supplements; Drug Therapy, Combination; Female; Fructose; Humans; Male; Middle Aged; Osteoarthritis; Radiography; Severity of Illness Index; Sulfonamides; Treatment Outcome; Ultrasonography